Marc N. Casper Sells 8,000 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) Stock

Key Points

• CEO Marc N. Casper sold 8,000 shares of Thermo Fisher Scientific at an average price of $454.45, totaling approximately $3.64 million, resulting in a 6.49% decrease in his ownership.
• Thermo Fisher Scientific recently reported earnings of $5.36 per share for the last quarter, surpassing estimates and generating $10.86 billion in revenue, up 2.9% year-over-year.
• The company announced a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, set to be paid on October 15th.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 8,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $454.45, for a total value of $3,635,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,340,824.30. This trade represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Thermo Fisher Scientific Stock Up 1.4%

Thermo Fisher Scientific stock traded up $6.15 during mid-day trading on Thursday, hitting $455.09. The company had a trading volume of 1,490,140 shares, compared to its average volume of 3,299,804. The stock has a market cap of $171.85 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.40 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $424.58 and a 200 day moving average of $465.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.37 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Analysts Set New Price Targets

TMO has been the topic of a number of research reports. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Royal Bank Of Canada cut their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently made changes to their positions in TMO. Brighton Jones LLC lifted its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after acquiring an additional 461 shares during the last quarter. FIL Ltd raised its stake in Thermo Fisher Scientific by 58.5% during the 4th quarter. FIL Ltd now owns 347,139 shares of the medical research company's stock valued at $180,592,000 after acquiring an additional 128,095 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Thermo Fisher Scientific by 270.5% during the 4th quarter. Renaissance Technologies LLC now owns 181,344 shares of the medical research company's stock valued at $94,341,000 after acquiring an additional 132,393 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.